Hydroxyurea is used to treat chronic myelocytic leukemia, ovarian cancer, and certain types of skin cancer (melanoma and primary squamous cell cancer of the head and neck).
Hydroxyurea is also used to reduce pain episodes and the need for blood transfusions in people with sickle cell anemia. Hydroxyurea will not cure sickle cell anemia.
Hydroxyurea may also be used for purposes not listed in this medication guide.
Used for: Treating skin cancer, cancer of the ovary, or chronic myelocytic leukemia that is recurrent, has spread, or cannot be helped with surgery. It may also be used with radiation to control skin cancers of the head and neck. It may also be used for other conditions as determined by your doctor.
Hydrea is an antineoplastic agent. It works by preventing necessary steps for cancer cell growth and reproduction, resulting in cell death.
Hydrea has dose-dependent synergistic activity with cisplatin in vitro. In vivo Hydrea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydrea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydrea 4 hours before cisplatin produced the greatest interaction.
Indication: For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Hydroxyurea is used to treat melanoma (a type of skin cancer), chronic myelocytic leukemia, cancer of the ovary, and primary squamous cell (skin) cancer of the head and neck. Hydroxyurea is also used to treat sickle cell anemia.
Hydrea is used to treat cancer. It is used to treat skin cancer, cancer of the ovaries and cancer of the white blood cells (also known as leukaemia). Hydrea may also be used together with radiotherapy (also known as radiation treatment) for specific types of skin cancers. Hydrea interferes with the growth of cancer cells.